trial · primary record
Foralumab Nasal
ALS (Amyotrophic Lateral Sclerosis)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 44 |
| Primary completion | 2027-11 |
| Primary endpoint | Safety - Occurrence of serious and non-serious treatment emergent adverse events and clinically significant treatment emergent abnormalities. |
| Registry ID | NCT07688239 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:04.254Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07688239
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.